Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Trinity Biotech (TRIB) Research & Development (2016 - 2024)

Trinity Biotech's Research & Development history spans 16 years, with the latest figure at -$1.5 million for Q4 2024.

  • On a quarterly basis, Research & Development fell 30.08% to -$1.5 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$4.5 million, a 3.75% decrease, with the full-year FY2025 number at $3.6 million, down 20.12% from a year prior.
  • Research & Development hit -$1.5 million in Q4 2024 for Trinity Biotech, down from -$1.0 million in the prior quarter.
  • Over the last five years, Research & Development for TRIB hit a ceiling of -$860000.0 in Q1 2023 and a floor of -$1.5 million in Q4 2024.
  • Historically, Research & Development has averaged -$1.1 million across 5 years, with a median of -$1.1 million in 2023.
  • Biggest five-year swings in Research & Development: surged 32.85% in 2022 and later plummeted 30.08% in 2024.
  • Tracing TRIB's Research & Development over 5 years: stood at -$1.3 million in 2020, then increased by 26.71% to -$941000.0 in 2021, then fell by 23.91% to -$1.2 million in 2022, then rose by 4.2% to -$1.1 million in 2023, then plummeted by 30.08% to -$1.5 million in 2024.
  • Business Quant data shows Research & Development for TRIB at -$1.5 million in Q4 2024, -$1.0 million in Q3 2024, and -$991000.0 in Q2 2024.